Home › Compare › SIOX vs MAIN

SIOX vs MAIN: Dividend Comparison 2026

SIOX yields 91.00% · MAIN yields 8.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SIOX wins by $2.62M in total portfolio value
10 years
SIOX
SIOX
● Live price
91.00%
Share price
$0.48
Annual div
$0.44
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.68M
Annual income
$847,016.42
Full SIOX calculator →
MAIN
Main Street Capital Corporation
● Live price
8.41%
Share price
$52.80
Annual div
$4.44
5Y div CAGR
5.1%
Payout ratio
82%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.2K
Annual income
$2,355.47
Full MAIN calculator →

Portfolio growth — SIOX vs MAIN

📍 SIOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSIOXMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SIOX + MAIN cover 8 of 12 months — good coverage

Jan
MAIN
Feb
MAIN
Mar
—
Apr
—
May
—
Jun
—
Jul
MAIN
Aug
MAIN
Sep
MAIN
Oct
MAIN
Nov
MAIN
Dec
MAIN
SIOX pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SIOX
Annual income on $10K today (after 15% tax)
$7,735.36/yr
After 10yr DRIP, annual income (after tax)
$719,963.96/yr
MAIN
Annual income on $10K today (after 15% tax)
$714.77/yr
After 10yr DRIP, annual income (after tax)
$2,002.15/yr
At 15% tax rate, SIOX beats the other by $717,961.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SIOX + MAIN for your $10,000?

SIOX: 50%MAIN: 50%
100% MAIN50/50100% SIOX
Portfolio after 10yr
$1.37M
Annual income
$424,685.95/yr
Blended yield
31.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

SIOX
Analyst Ratings
1
Buy
2
Hold
1
Sell
Consensus: Hold
Altman Z
-17.3
Piotroski
2/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.6% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SIOX buys
0
MAIN buys
1
PoliticianChamberTickerTypeAmountDate
David Cheston Rouzer🏢 House$MAIN▼ Sell$15,001 - $50,0002021-11-15
David Cheston Rouzer🏢 House$MAIN▲ Buy$1,001 - $15,0002019-02-28
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSIOXMAIN
Forward yield91.00% ✓8.41%
Annual dividend / share$0.44$4.44 ✓
Payout ratio50% ✓82%
1-year div growth0%3.7% ✓
5-year div CAGR0%5.1% ✓
Portfolio after 10y$2.68M$57.2K ✓
Annual income after 10y$847,016.42 ✓$2,355.47
Total dividends collected$2.37M$15.5K ✓
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusHoldHold

Year-by-year: SIOX vs MAIN ($10,000, DRIP)

YearSIOX PortfolioSIOX Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$19,800$9,100.42$12,124$883.80+$7.7K → SIOX
2$38,027$16,840.38$14,629$1,001.91+$23.4K → SIOX
3$70,915$30,226.23$17,573$1,130.42+$53.3K → SIOX
4$128,559$52,680.24$21,022$1,269.75+$107.5K → SIOX
5$226,813$89,254.37$25,049$1,420.29+$201.8K → SIOX
6$389,856$147,166.82$29,738$1,582.45+$360.1K → SIOX
7$653,555$236,408.67$35,182$1,756.64+$618.4K → SIOX
8$1,069,692$370,388.16$41,488$1,943.25+$1.03M → SIOX
9$1,711,136$566,565.23$48,775$2,142.72+$1.66M → SIOX
10$2,677,932$847,016.42$57,179$2,355.47+$2.62M → SIOX

SIOX vs MAIN: Complete Analysis 2026

SIOX — Stock

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Full SIOX Calculator →

MAIN — BDC

Main Street Capital is a Business Development Company providing debt and equity capital to lower middle market companies. It pays regular monthly dividends plus semi-annual special dividends. One of the few BDCs consistently trading at a premium to NAV, with an exceptional track record since its 2007 IPO. Often called the gold standard of BDCs.

Full MAIN Calculator →
📬

Get this SIOX vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SIOX vs SCHDSIOX vs JEPISIOX vs OSIOX vs KOSIOX vs ARCCSIOX vs HTGCSIOX vs GBDCSIOX vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.